Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer

June 09, 2021 By The ASCO Post Staff

Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).

Related Content